Astellas Pharma Inc. has divulged substituted quinolone derivates acting as acetylcholine receptor cluster inducers reported to be useful for the treatment of neuromuscular disorders.
Shanghai Haiyan Pharmaceutical Technology Co. Ltd. and Yangtze River Pharmaceutical Group have synthesized macrophage colony-stimulating factor 1 receptor (CSF-1R; CD115; c-Fms) inhibitors reported to be useful for the treatment of cancer.
Researchers at Association Française Contre Les Myopathies, Consiglio Nazionale delle Ricerche, and Università degli Studi di Roma La Sapienza have disclosed peptidomimetics derived from leucyl-tRNA synthetase.
Researchers from Arizona State University presented preclinical data for the novel dual specificity tyrosine phosphorylation kinase 1a (DYRK1a) inhibitor DYR-533, being developed for the treatment of tauopathies, including Alzheimer’s disease (AD).
Krystal Biotech Inc. has received FDA acceptance of its IND application for lead oncology drug candidate KB-707 for the treatment of locally advanced or metastatic solid tumor malignancies. KB-707 is a modified herpes simplex virus 1 (HSV-1) vector designed to deliver genes encoding both human IL-12 and IL-2 to the tumor microenvironment and promote systemic immune-mediated tumor clearance.
An mRNA vaccine candidate that acts in the liver by recruiting memory T cells could be the key against malaria, according to a study in mice that demonstrated its efficacy by including a natural killer T (NKT) cell agonist.
A team of scientists led by The Wistar Institute has been awarded a 5-year National Cancer Institute (NCI) Program Project Grant valued at more than $12 million to explore the role of Epstein-Barr virus (EBV) in epithelial cancers. The project, which brings together scientists from The Wistar Institute and Harvard University, will focus entirely on the EBV-epithelial cancer link and look at metabolic and epigenetic vulnerabilities simultaneously.
Researchers from China Pharmaceutical University have disclosed the discovery and preclinical evaluation of a new receptor-interacting serine/threonine-protein kinase 2 (RIPK2) inhibitor, Zharp2-1, as a potential therapeutic candidate for the treatment of inflammatory bowel disease (IBD).
RSS
